AbbVie's experimental drug upadacitinib met its goal of stopping progression of moderate-to-severe rheumatoid arthritis in a late-stage trial. It was tested as a monotherapy in patients who have not been treated with methotrexate, a chemotherapy agent.
The med is a JAK inhibitor, which work by blocking inflammation-causing enzymes known as Janus kinases. AbbVie is planning to submit a U.S. marketing application in the second half of 2018.
Read the Reuters report